Participated · Series B · Jan 2026

Tenpoint Therapeutics, Ltd. is a global commercial biotech company focused on rejuvenating vision in the aging eye. Its lead product, YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution 2.75% / 0.1%), is the first and only dual-agent eye drop approved for presbyopia, a condition that affects about 128 million people in the United States and roughly 2 billion worldwide. The company plans to launch YUVEZZI in early Q2, supported by a leadership team with extensive ophthalmology experience. Tenpoint emphasizes real-world needs by partnering closely with eye-care professionals to bring innovative treatments to market. Financially, the firm recently bolstered its balance sheet with $85 million in Series B equity financing and a $150 million non-dilutive term loan facility, bringing in both new and existing blue-chip investors. This capital positions Tenpoint to execute a large-scale commercial rollout while continuing to build its pipeline of therapies for the aging eye.

Led · Series A · Sep 2025

Founded in 2023, Dualitas Therapeutics is building a pipeline of bispecific antibodies that simultaneously engage two immune-cell targets to achieve greater efficacy than single-target monoclonal antibodies. Its internally developed DualScreen platform scans the entire cell surface (“surfaceome”) to identify hundreds of thousands of target pairings and select the most promising therapeutic combinations using a proximity-biology approach. The two lead preclinical candidates are DTX-103, aimed first at asthma and other allergic diseases, and DTX-102, initially focused on rheumatoid arthritis; specific targets for both remain undisclosed. One of these programs is expected to be advanced in-house, while the other may be partnered with a larger pharmaceutical company. Management plans to move the internal lead into clinical trials within 18–24 months and will evaluate clinical differentiation versus current standards of care to guide trial design. The company’s scientific leadership includes co-founders Forbes Huang (COO/CBO) and Greg Lazar (CSO), with Rich Murray serving as interim CEO.

Participated · Series A · May 2025

Rhino Federated Computing provides a platform for federated AI collaboration that enables enterprises to run AI and data science initiatives without centralizing data. The platform emphasizes protecting data ownership, complying with regulation, and accelerating multi‑party innovation. Founded in 2020 by Dr. Ittai Dayan and Yuval Baror, the company is based in Boston and maintains an R&D center in Tel Aviv. Rhino is already powering use cases including federated GenAI for biopharmaceutical R&D, healthcare data harmonization and federated collaboration, and financial‑crime and fraud detection for financial institutions. The company raised $15M in a Series A and has now raised over $30M to date. Rhino plans to use the new capital to scale capabilities across more customers and regulated sectors and to bring an enterprise‑grade federated AI solution to market. Rhino Health builds healthcare AI infrastructure that connects medical data sources with researchers while preserving patient privacy and IP confidentiality. The company develops solutions using federated learning and edge computing to enable secure, decentralized data processing and AI model training. Rhino Health has enabled partners to create networks of health systems, life sciences companies, and public sector organizations for cross-continent data collaborations. Led by CEO Dr. Ittai Dayan, the company emphasizes privacy-preserving approaches to accelerate healthcare research. The company received an investment intended to fund continued design of its federated and edge computing solutions; the amount was not disclosed. Rhino Health operates a platform that connects hospitals and AI developers, providing access to a large, continually updated, distributed dataset from a diverse group of patients. The core product enables clinical AI model development across different institutions and patient demographics. Rhino is collaborating with NVIDIA to bring federated learning into clinical settings and is using NVIDIA Clara to support cross-geography and cross-device model training. The company is a member of the NVIDIA Inception program and maintains an R&D center in Tel Aviv, Israel. Rhino closed a $5M seed financing round led by LionBird Ventures, with participation from Arkin Holdings and several angel investors. The company is led by CEO Ittai Dayan, MD, and CTO Yuval Baror.

Participated · Series C · Jan 2025

Umoja Biopharma is a clinical-stage biotechnology company developing in vivo cell therapies to expand the reach, effectiveness, and access of CAR T treatments. Its VivoVec™ in vivo gene delivery technology is designed to empower a patient’s own immune system to fight disease by delivering therapeutic constructs directly in vivo. The company’s lead program is CD22 UB-VV400, which it plans to advance in multiple oncology and autoimmune clinical studies. Umoja intends to use proceeds from its recent financing to advance this in vivo CAR T pipeline. The company is led by CEO Andrew Scharenberg and is based in Seattle, Washington. In conjunction with the financing, Umoja added Campbell Murray, M.D., as a new board member. Umoja Biopharma leverages proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for solid tumors and hematologic malignancies. Its platform includes CAR T-cell adapter-mediated tumor-targeting (TumorTag) and in vivo modification of immune cells (VivoVec and RACR/CAR). The company’s two lead programs are TumorTag UB-TT170 for folate receptor-expressing solid tumors and VivoVec UB-VV100 for CD19+ hematological cancers. Umoja will use proceeds from a $210M Series B to continue development of its integrated technologies and advance these product candidates into clinical development. The company also plans to build internal manufacturing capabilities to support preclinical and clinical development and to expand its team. Recent leadership hires include Nushmia Khokhar as Chief Medical Officer, Irena Melnikova as Chief Financial Officer and David Fontana as Chief Business and Strategy Officer, and Umoja is establishing a manufacturing operations site in Boulder, Colorado. Umoja Biopharma is a Seattle-based, pre-clinical biotechnology company pioneering an integrated in vivo immunotherapy platform. Its platform combines three core components: the VivoVec delivery platform, RACR/CAR payload architecture, and the TumorTag platform. VivoVec acts in vivo to generate a population of cancer-fighting VivoCAR T cells that can be controlled by the RACR/CAR system using exogenously administered, FDA-approved drugs. TumorTag molecules can be used in combination with VivoCAR T cells to direct cancer-killing T cells to tumors and their critical supporting cells. Led by co-founders Andy Scharenberg, M.D., and Michael Jensen, M.D., the company aims to re-engineer a patient's immune system to attack both hematologic and solid organ-based tumors with simplicity and cost that enable widespread implementation. The $53M Series A financing will enable Umoja to advance its platform and therapeutic programs to early clinical development, attract talent and invest in research.

Participated · Series B · Dec 2024

Soda Health operates a smart benefits technology platform that connects members to products and services—like healthy foods, OTC medications, and transportation—through partnerships with health plans and retailers. The platform offers a consumer-grade member experience and tools for health plans to design, launch, and scale benefit programs supported by a broad retail network and analytics. Retail partners use the platform to integrate pharmacies and dietitians into care delivery and drive high ROI benefit spend. Led by CEO Robby Knight, the company emphasizes personalized, efficient benefit delivery to improve health outcomes and reduce inequities. Soda Health raised $50M in a Series B to support growth and continue product development. The company plans to use the funds to broaden its data products and services and to expand support for new benefit categories. Soda Health provides a technology platform to administer and reimburse supplemental benefits personalized to individual needs and delivered cost-effectively. Its system streamlines how individuals are matched with supplemental benefits from their health insurance plan and simplifies the member experience to use those resources. The company is remote-first, headquartered in Bentonville, Ark., and also maintains offices in Chicago. Leadership includes CEO Robby Knight, President and Chief Growth Officer Daryl Risinger, and Head of Operations Jared Dauman. Soda Health raised new capital to support expansion of operations and to grow its business reach. The platform is positioned to improve access to health by making supplemental benefits easier to find and use. Soda Health provides a technology platform that bridges medical claims and retail payments to deliver health care–centric payments and reimbursements for benefits not supported by traditional claims. The company aims to make healthcare transactions more like retail purchases, including use of debit‑card‑style payments, to reduce friction for consumers. Soda Health’s platform is designed to help health plans cost‑effectively administer personalized supplemental benefits while increasing utilization and sustained engagement. The company positions its products to eliminate health inequities by improving access to goods and services critical to health when financial resources are a barrier. Soda Health highlights an addressable market that includes nearly 20 million Medicare Advantage beneficiaries with supplemental benefits for OTC medications and wellness items. The company launched in Bentonville, Ark., and recently closed seed financing to support its product and go‑to‑market efforts.